Pediatric Cancer Studies: US FDA’s Molecular Target Lists Face Panel Vetting

 
• By Sue Sutter

In addition to reviewing proposed lists of targets for relevance to pediatric cancer, advisory committee will discuss possible criteria for prioritizing same-in-class agents for evaluation and ways to promote international collaboration and global development; proposed list of substantially relevant targets is growing.

Target hit in center by arrows. 3d illustration. Sunrise on background
A drug aimed at a molecular target that is substantially relevant to pediatric cancer might face additional studies under a recent US law.

More from US FDA Performance Tracker

More from Regulatory Trackers